Insilico Medicine has announced a strategic partnership with Seto Bio (SHE: 300583) to harness cutting-edge AI technology to explore and optimize key steps in the engineering transformation of biological systems, advancing synthetic biology research and innovative drug development.
Established in 2014, Insilico Medicine has built over 30 proprietary drug pipeline combinations under its artificial intelligence platform, Pharma.AI. Seto Bio, founded in 2010, is a leading supplier of domestic steroid drug raw materials in China, with a comprehensive product line covering the five major mother nuclei of steroid drugs. This collaboration will rely on the powerful capabilities of Insilico Medicine’s generative AI platform, Pharma.AI, and the expertise of its drug research and development team, combined with Seto Bio’s complete synthetic biology R&D chain and large-scale fermentation capabilities. Together, they aim to overcome key challenges in fermentation technology engineering and accelerate the research and development progress of synthetic biology and innovative drugs.- Flcube.com
